Innate Pharma SA
NASDAQ:IPHA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
NASDAQ:IPHA
|
FR |
|
B
|
Bonterra Energy Corp
OTC:BNEFF
|
CA |
|
DEV Information Technology Ltd
NSE:DEVIT
|
IN |
|
Guardant Health Inc
F:5GH
|
US |
|
Schneider Electric SE
PAR:SU
|
FR |
|
D
|
Dios Exploration Inc
XBER:BFM
|
CA |
|
Egide SA
PAR:ALGID
|
FR |
|
S
|
SEB SA
XMUN:GRB
|
FR |
Wall St Price Targets
IPHA Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for IPHA is 6.78 USD with a low forecast of 5.64 USD and a high forecast of 8.08 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPHA's stock price target?
Price Target
6.78
USD
According to Wall Street analysts, the average 1-year price target for IPHA is 6.78 USD with a low forecast of 5.64 USD and a high forecast of 8.08 USD.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
Over the last 14 years, the compound annual growth rate for Revenue has been -7%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
1 086%
The compound annual growth rate for Gross Profit over the next 3 years is 1 086%.
